Pegloticase
Wikipedia on Answers.com:
Top
Pegloticase
| Clinical data | |
|---|---|
| Trade names | Krystexxa |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a611015 |
| Licence data | US FDA:link |
| Pregnancy cat. | C (US) |
| Legal status | ℞-only (US) |
| Routes | Intravenous |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Half-life | 10–12 days |
| Identifiers | |
| CAS number | 885051-90-1  |
| ATC code | M04AX02 |
| UNII | R581OT55EA  |
| KEGG | D09316 |
| ChEMBL | CHEMBL1237025 |
| Chemical data | |
| Formula | C1549H2430N408O448S8 (peptide monomer) |
| Mol. mass | 497 kDa (polymer-modified tetramer) |
 (what is this?) (verify) |
|
Pegloticase (trade name Krystexxa, formerly Puricase)[1] is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.[2][3] In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.
The drug is administered intravenously.
|
Contents
|
Mechanism of action
Pegloticase is a recombinant porcine-like uricase. Similarly to rasburicase, it metabolises uric acid to allantoin. This reduces the risk of precipitates, since allantoin is five to ten times more soluble than uric acid.
In contrast to rasburicase, pegloticase is pegylated to increase its elimination half life from about eight hours to ten or twelve days and to decrease the immunogenicity of the foreign uricase protein. This modification allows for an application just once every two to four weeks, making this drug suitable for long-term treatment.[4]
Side effects
Pegloticase may show immunogenicity.[5]
Chemistry
Pegloticase is a tetrameric peptide composed of four identical chains of about 300 amino acids each. Approximately nine out of the 30 lysine residues in each chain are pegylated. These side chains consist of about 225 ethylene glycol units each.[2]
References
- ^ Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress
- ^ a b Statement on a nonproprietary name adopted by the USAN Council
- ^ Savient Pharmaceuticals: Uricase
- ^ Biggers, K; Scheinfeldt, N (2008). Current Opin. Investig. Drugs 9 (4): 422–429.
- ^ Abraham J. Domb, Neeraj Kumar (2 August 2011). Biodegradable Polymers in Clinical Use and Clinical Development. John Wiley & Sons. http://books.google.com/books?id=LUOQu6_kLZQC&dq=immunogenicity+Pegloticase&source=gbs_navlinks_s.
External links
- Krystexxa (pegloticase) Injection, for intravenous infusion: Full prescribing information
|
||||||||||||||||||||||
 |
This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Pegloticase.
Read more